In Parkinson's disease with dementia, up to 50% of patients develop a high number of tau‐
containing neurofibrillary tangles. Tau‐based pathologies may thus act synergistically with …

Aggregation of α-synuclein leads to the formation of oligomeric intermediates that can
interact with membranes to form pores. However, it is unknown how this leads to cell toxicity …

α-Synuclein (α-syn) phosphorylation at serine 129 is characteristic of Parkinson disease
(PD) and related α-synulceinopathies. However, whether phosphorylation promotes or …

The aggregation of α-synuclein, involved in the pathogenesis of several neurodegenerative
disorders such as Parkinson's disease, is enhanced in vitro by biogenic polyamines binding …

Alpha-synuclein (α-syn) is the major component of intracellular inclusions in several
neurodegenerative diseases, and the conversion of soluble α-syn into filamentous …

The aggregation of α-synuclein (AS) is characteristic of Parkinson's disease and other
neurodegenerative synucleinopathies. We demonstrate here that Cu (II) ions are effective in …

Amyloid proteins are involved in many neurodegenerative disorders such as Alzheimer's
disease [Tau, Amyloid β (Aβ)], Parkinson's disease [alpha-synuclein (αSyn)], and …

Lewy bodies (LBs), which are the hallmark pathologic features of Parkinson's disease and of
dementia with LBs, have several morphologic and molecular similarities to aggresomes …

Lewy bodies, α‐synuclein (α‐syn) immunopositive intracellular deposits, are the
pathological hallmark of Parkinson's disease (PD). Interestingly, Lewybody‐like structures …

Abnormal accumulation of aggregated α-synuclein (α-Syn) is seen in a variety of
neurodegenerative diseases, including Parkinson's disease (PD), multiple system atrophy …